Waverley Pharma Inc. WAVE.V
TSX
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 8.55% | -1.74% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 8.55% | -1.74% | |||
| Cost of Revenue | 3.61% | 10.41% | |||
| Gross Profit | 18.77% | -19.95% | |||
| SG&A Expenses | -4.37% | -18.53% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.33% | -7.12% | |||
| Operating Income | 21.09% | 17.65% | |||
| Income Before Tax | 13.93% | 14.77% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 13.93% | 14.77% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 13.93% | 14.77% | |||
| EBIT | 21.09% | 17.65% | |||
| EBITDA | 25.30% | 24.09% | |||
| EPS Basic | 13.64% | 15.38% | |||
| Normalized Basic EPS | 14.29% | 12.50% | |||
| EPS Diluted | 13.64% | 15.38% | |||
| Normalized Diluted EPS | 14.29% | 12.50% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||